Anti-Mouse CD209b [Clone 22D1] - Purified <i>in vivo </i>GOLD™ Functional Grade (C2859-1.0mg)

CD209b has a molecular weight of 37 kD and is a single-pass type II membrane protein containing a C-type lectin domain. CD209b plays a role in innate immune response, mediating the recognition and uptake of pathogen products such as lipopolysaccharides, pneumococcal polysaccharides, and dextrans. CD209b is a mouse homolog of human CD209, also known as DC-SIGN. Both primates and mice have several paralogs of CD209 that, within the species, are more comparable to each other than to orthologs of other species. Although DC-SIGN expression is similar in function and dendritic expression in both mice and humans, they are not unique orthologs. Higher primates have at least three DC-SIGN genes (DC-SIGN, DC-SIGNL1 and DC-SIGNL2); although DC-SIGNL2 has not been detected in humans. Up to eight paralogs of DC-SIGN have been reported in some laboratory mouse strains, some of which are differentially expressed on different cell types. On macrophages, DC-SIGN activates phagocytosis via the recognition and binding of mannose type carbohydrates, a class of pathogen associated molecular patterns (PAMPs) frequently found on viruses, bacteria and fungi. On myeloid and pre-plasmacytoid dendritic cells, DC-SIGN initiates immune response via the recognition of pathogen haptens (which elicits the production of antibodies), in addition to the mediation of dendritic cell rolling interactions with blood endothelium and activation of CD4+ T cells. Furthermore, DC-SIGN functions as receptor for viruses such as HIV and Hepatitis C. DC-SIGN, in conjunction with other C-type lectins, also plays a role in the recognition of tumors via dendritic cells. Hence, the therapeutic potential for DC-SIGN as a target for dendritic cell based cancer vaccine.